vimarsana.com
Home
Live Updates
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights : vimarsana.com
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in...
Related Keywords
United States
,
Cyprus
,
Dana Cormack
,
Eli Lilly
,
Chris Brinzey
,
Ultragenyx Pharmaceutical Inc
,
Technology Platform
,
Technology Platform Licensees
,
Rocket Pharmaceuticals Inc
,
Nasdaq
,
Novartis
,
Technology Licensee Program
,
Exchange Commission
,
Development Expenses
,
Therapeutics Inc
,
Corporate Communications
,
Securities Exchange
,
Manufacturing Innovation Center
,
Chief Executive Officer
,
Biologics Licensing Application
,
Duchenne Muscular Dystrophy
,
Mucopolysaccharidosis Type
,
Hunter Syndrome
,
Innovation Center
,
Licensee Program
,
Rocket Pharmaceuticals
,
Prevail Therapeutics Inc
,
Ultragenyx Pharmaceutical
,
Ornithine Transcarbamylase
,
Administrative Expenses
,
Platform Licensees
,
Securities Act
,
Securities Exchange Act
,
Financial Condition
,
Tax Benefit
,
Comprehensive Income
,
Regenxbio Inc
,
vimarsana.com © 2020. All Rights Reserved.